Venous congestion and endothelial cell activation in acute decompensated heart failure

被引:58
作者
Ganda A. [1 ]
Onat D. [2 ]
Demmer R.T. [3 ]
Wan E. [4 ]
Vittorio T.J. [5 ]
Sabbah H.N. [6 ]
Colombo P.C. [7 ]
机构
[1] Division of Nephrology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, 622 West 168th Street
[2] Division of Cardiology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, 630 West 168th Street
[3] Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY 10032
[4] Division of Cardiology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, 622 West 168th Street
[5] Division of Cardiology, Mount Sinai Medical Center, Box 1030, New York, NY 10029, One Gustave L. Levy Place
[6] Division of Cardiovascular Medicine, Henry Ford Heart and Vascular Institute, Detroit, MI 48202
[7] Division of Cardiology, College of Physicans and Surgeons, Columbia University, New York, NY 10032, 622 West 168th Street
基金
美国国家卫生研究院;
关键词
Congestion; Endothelium; Heart failure; Inflammation;
D O I
10.1007/s11897-010-0009-5
中图分类号
学科分类号
摘要
Despite accumulating clinical evidence supporting a key role for venous congestion in the development of acute decompensated heart failure (ADHF), there remain several gaps in our knowledge of the pathophysiology of ADHF. Specifically, the biomechanically driven effects of venous congestion on the vascular endothelium (the largest endocrine/ paracrine organ of the body), on neurohormonal activation, and on renal and cardiac dysfunction remain largely unexplored. We propose that venous congestion is a fundamental, hemodynamic stimulus for vascular inflammation, which plays a key role in the development and possibly the resolution of ADHF through vascular, humoral, renal, and cardiac mechanisms. A better understanding of the role of venous congestion and endothelial activation in the pathophysiology of ADHF may provide a strong rationale for near-future testing of treatment strategies that target biomechanically driven inflammation. Targeting vascular and systemic inflammation before symptoms arise may prevent progression to overt clinical decompensation in the ADHF syndrome. © Springer Science+Business Media, LLC 2010.
引用
收藏
页码:66 / 74
页数:8
相关论文
共 72 条
[1]  
Lloyd-Jones D., Adams R., Carnethon M., Et al., Heart disease and stroke statistics-2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Circulation, 119, pp. 480-486, (2009)
[2]  
Gheorghiade M., Zannad F., Sopko G., Klein L., Pina I.L., Konstam M.A., Massie B.M., Roland E., Targum S., Collins S.P., Filippatos G., Tavazzi L., Acute heart failure syndromes: Current state and framework for future research, Circulation, 112, 25, pp. 3958-3968, (2005)
[3]  
Fonarow G.C., Heywood J.T., Heidenreich P.A., Et al., Temporal trends in clinical characteristics treatments and outcomes for heart failure hospitalizations 2002 to 2004,: Findings from Acute Decompensated Heart Failure National Registry (ADHERE), Am Heart J, 2007, 153, pp. 1021-1028
[4]  
Yu C.M., Wang L., Chau E., Et al., Intrathoracic impedance monitoring in patients with heart failure: Correlation with fluid status and feasibility of early warning preceding hospitalization, Circulation, 112, pp. 841-848, (2005)
[5]  
Chaudhry S.I., Wang Y., Concato J., Et al., Patterns of weight change preceding hospitalization for heart failure, Circulation, 116, pp. 1549-1554, (2007)
[6]  
Lucas C., Johnson W., Hamilton M.A., Et al., Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure, Am Heart J, 140, pp. 840-847, (2000)
[7]  
Gheorghiade M., Gattis W.A., O'Connor C.M., Et al., Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled tria, JAMA, 291, pp. 1963-1971, (2004)
[8]  
Adamson P.B., Magalski A., Braunschweig F., Et al., Ongoing right ventricular hemodynamics in heart failure: Clinical value of measurements derived from an implantable monitoring system, J Am Coll Cardiol, 41, pp. 565-571, (2003)
[9]  
Fonarow G.C., Abraham W.T., Albert N.M., Et al., Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: Findings from OPTIMIZE-HF, Arch Intern Med, 168, pp. 847-854, (2008)
[10]  
Tsuyuki R.T., McKelvie R.S., Arnold J.M., Et al., Acute precipitants of congestive heart failure exacerbations, Arch Intern Med, 161, pp. 2337-2342, (2001)